Akay Group’s curcuminoid-fenugreek complex, CurQfen, was found to be more effective than glucosamine hydrochloride and chondroitin sulfate at reducing the pain and symptoms of osteoarthritis (OA) patients.
The randomized trial found this to be the case even at very low doses of CurQfen, spotlighting the importance of bioavailability.
“Significant absorption, distribution and cellular uptake of the bioactive form of the molecules are very important for the functional and therapeutic efficacy of any substance,” Dr. Krishnakumar IM, Akay’s chief research officer, tells NutritionInsight.
Read More : Click here
